Pierre Benite

• Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma Recruiting
  2024-519208-29-00 4 2026-04-02 Pleural mesothelioma
• Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs Recruiting
  2025-523297-16-00 1 2026-02-27 Non-Hodgkin Lymphoid Malignancies (NHLs)
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum … Recruiting
  2025-520897-21-00 10 2026-02-25 Multiple Myeloma
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer Recruiting
  2025-521904-23-00 4 2026-02-17 Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to
• Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA- … Recruiting
  2025-522703-14-00 5 2026-02-17 "Moderate to severe obstructive sleep apnea (OSA) in adults living wit
• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated … Recruiting
  2024-515948-23-00 5 2026-02-06 Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Part … Recruiting
  2025-522151-26-00 5 2026-02-06 Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growt
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• A Study to test ALE.P03 in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors Recruiting
  2025-521441-24-00 7 2026-01-19 Advanced or Metastatic Solid Tumors
• A study to find a suitable dose of ASP5834 in adults with solid tumors Recruiting
  2025-522082-29-00 1 2026-01-16 Locally advanced (unresectable) or metastatic solid tumor malignancies
• NEOREM/NEO-1 - NEOREM: Neo-adjuvant Immunotherapy Master Trial for Localized Cancers / NEO-1: Neo-adjuvant immunotherapy in patients with l … Recruiting
  2025-522127-95-00 4 2026-01-12 NEOREM: Localized solid malignancies that are eligible to receive neo-
• Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou … Recruiting
  2025-521144-38-00 4 2025-12-23 Primary Central Nervous System Lymphoma
• WIthdrawal of DUpilumab in Severe Asthma : a randomised non-inferiority-controlled trial Recruiting
  2024-516789-13-00 6 2025-12-15 Severe asthma
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic pla … Recruiting
  2024-511003-42-00 4 2025-12-11 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting
  2024-517136-21-00 5 2025-12-05 Renal Cell Carcinoma
• Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2025-521382-27-00 10 2025-12-04 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting
  2025-521242-26-00 4 2025-11-27 Moderately to Severely Active Ulcerative Colitis
• Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with … Recruiting
  2024-519048-33-00 10 2025-11-25 resected pancreatic adenocarcinoma
• Momelotinib in VEXAS syndrome Recruiting
  2024-519779-24-00 4 2025-11-25 VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, SOMATIC) syndr
• Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-520927-26-00 5 2025-11-24 Metastatic Castration-resistant Prostate Cancer (mCRPC)

Showing 97–120 of 404 trials